Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Summary
The bill authorizes Medicaid to count several best‑price options for a single drug when the drug is sold under a value‑based purchasing arrangement, and it adjusts how those prices are reported for Medicare and Medicaid rebates. It also requires the GAO to study the impact of such arrangements and directs CMS to issue guidance for states on covering inpatient drugs through these deals. The changes aim to improve how high‑cost treatments, like gene therapies, are paid for while protecting patients and programs.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Topics
Track this bill
Get real-time alerts when HR 7871 changes status, plus AI-powered summaries and stage predictions.
Sign up free